CA
NZ
UK
AU
IND
US
● Peers Gilead, Regeneron, Vertex and Eli Lilly also traded higher in the pre-market session.
● A brokerage downgraded the stock to Market Perform with an $8 price target.
● Enhertu won European approval on October 27 for HER2-positive early breast cancer with residual disease.
● Bicara'sMarket Valueis about $646 million versus $497.3 million cash at June 30.
● Full-year 2026 adjusted EPS guidance was cut to $3.16 to $3.18.
● Normalized non-acquired treatment growth was a modest 0.4% year over year.
● Yeztugo generated $305 million, up from $39 million a year earlier.
● Drugmakers rallied alongside GSK as Nasdaq-100 futures fell about 2.6% on AI spending worries.
● Opzelura sales rose 36% to $255 million while Jakafi grew 4%.
● Kymera had $1.5 billion in cash and investments as of June 30, 2026.
Please wait processing your request...